



Press release

SHL Telemedicine Ltd. terminates transaction with Shanghai Jiuchuan Investment (Group) Co., Ltd.

Tel Aviv / Zurich, 1 December 2015 – SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN, OTCPK: SMDCY) (“SHL”), a leading provider and developer of advanced personal telemedicine solutions, announced today that the company has terminated the Merger Agreement with Shanghai Jiuchuan Investment (Group) Co. Ltd. (“Shanghai Jiuchuan”). Shanghai Jiuchuan failed to fulfil the relevant closing conditions stipulated in the Merger Agreement dated as of 24 July 2015 by the extended period until 30 November 2015 granted by SHL in its letter dated 11 November 2015 per Shanghai Jiuchuan’s request. Therefore, the Merger Agreement is being terminated and the transaction cannot be consummated as originally planned.

SHL’s Board of Directors is evaluating strategic options of SHL and will communicate in due course.

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. The Company operates in Israel, Germany, India and the United States in one business segment, Telemedicine services. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and has an ADR program listed over-the counter; Symbol: SMDCY. For more information, please visit our web site at www.shl-telemedicine.com.

For further information please contact:

- Erez Alroy, Co-CEO, Phone: +972 3561 22 12, ereza@shl-telemedicine.com
- Martin Meier-Pfister, IRF Communications, Phone: +41 43 244 81 40, shl@irfcom.ch

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.